{"id":"W2981745131","doi":"","title":"A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","year":2019,"lang":"en","type":"article","venue":"PMC","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Antibody-drug conjugate; Internal medicine; Adverse effect; Nausea; Oncology; Germ cell tumors; Open label study; Mesothelioma; Phases of clinical research; Antibody; Toxicity; Chemotherapy; Lymphoma; Immunology; Pathology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001916347,0.000156049,0.0005001045,0.0001907111,0.00003847143,0.00003787529,0.000232682,0.00003492667,0.0001735217],"category_scores_gemma":[0.000109137,0.00012217,0.00001719462,0.0003529751,0.00005369309,0.0001255584,0.0001864967,0.0001825224,0.00004770498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001029145,"about_ca_system_score_gemma":0.0002115885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002891066,"about_ca_topic_score_gemma":0.00006830163,"domain_scores_codex":[0.9983224,0.00009746313,0.0003304809,0.0003572068,0.0005765862,0.0003158103],"domain_scores_gemma":[0.9990975,0.00005416388,0.0001092374,0.0004150597,0.0002282143,0.00009588273],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005167556,0.0445882,0.9379402,0.0001030202,0.00006990336,0.0000684485,0.00348224,0.00001127022,0.003843176,0.000003521495,0.00006368154,0.004658749],"study_design_scores_gemma":[0.4165663,0.04373365,0.5192063,0.001393975,0.00009695322,0.0000498029,0.008725488,0.002531416,0.007032278,0.00003022159,0.00008857833,0.0005451234],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951794,0.00004486385,0.000005037805,0.00004106251,0.00002907524,0.002829985,0.000009637438,0.00001391289,0.001847001],"genre_scores_gemma":[0.9991811,0.000001755914,0.0001432484,0.00004515932,0.00001039184,0.00005456373,0.00002263636,0.00003424157,0.0005069047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.418734,"threshold_uncertainty_score":0.4981947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03523732062145055,"score_gpt":0.3729277082655465,"score_spread":0.3376903876440959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}